The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
Future Oncol
; 18(4): 519-535, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-34851173
ABSTRACT
Aim:
To understand the burden of treatment-naive peripheral T-cell lymphoma (PTCL).Methods:
A systematic literature review was conducted in November 2020 following best practice methodology.Results:
Fifty-five clinical studies were included, mostly investigating cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or 'CHOP-like' regimens, with combination regimens showing similar effectiveness to CHOP alone. Aside from the combination of brentuximab vedotin + cyclophosphamide, doxorubicin and prednisone (A+CHP), other available treatments showed no statistically significant benefit over CHOP in terms of overall or progression-free survival in overall PTCL patients. The mean monthly cost per patient in the USA ranged from 6328 to US$9356 based on six studies. One economic evaluation demonstrated A+CHP to be a more cost-effective treatment option than CHOP.Conclusion:
Further research is needed to understand the humanistic and cost impact of frontline treatment for PTCL and its specific subtypes.
Plain language summary Peripheral T-cell lymphoma (PTCL) is an aggressive cancer that develops from white blood cells called T cells, which are an important part of the immune system. There is limited knowledge on the impact PTCL has on patients and their families. This systematic review of 55 clinical studies was conducted to further understand how safe and effective current treatments are for patients with newly diagnosed PTCL, how these treatments and disease impact their quality of life, and the economic impact of treatment and disease. Chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone [CHOP]) was the most commonly studied regimen, but had limited effectiveness and a notable side effect profile. A newer treatment option, brentuximab vedotin + cyclophosphamide, doxorubicin and prednisone (A+CHP) was the only treatment to show a significant added benefit over CHOP for patients, with side effects that were comparable to those of CHOP. Six studies assessed the economic impact of PTCL, the majority of which were focused on the USA, and found the mean monthly cost per patient to be 6328US$9356. No studies were identified that assessed the impact of PTCL or its treatment on quality of life. Further research is needed to understand the impact of frontline PTCL treatment on patients and their families.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, T-Cell, Peripheral
/
Cost of Illness
Type of study:
Guideline
/
Health_economic_evaluation
/
Systematic_reviews
Aspects:
Patient_preference
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Future Oncol
Year:
2022
Document type:
Article
Affiliation country:
Estados Unidos